Significance of QRS prolongation during diagnostic ajmaline test in patients with suspected Brugada syndrome

Heart Rhythm

Volumn 6, Issue 5, 2009, Pages 625-631

  Batchvarov, Velislav N ^a   Govindan, Malini ^a   Camm, A John ^a   Behr, Elijah R ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Ajmaline test; Brugada syndrome; Class I drugs; Conduction defects; Proarrhythmia; QRS prolongation; Ventricular arrhythmias

Indexed keywords

AJMALINE;

ADULT; AJMALINE TEST; ARTICLE; BRUGADA SYNDROME; DIAGNOSTIC TEST; ELECTROCARDIOGRAM; FALSE NEGATIVE RESULT; FEMALE; HEART ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QRS COMPLEX;

ADULT; AJMALINE; ANTI-ARRHYTHMIA AGENTS; BRUGADA SYNDROME; DIAGNOSIS, DIFFERENTIAL; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART CONDUCTION SYSTEM; HEART RATE; HUMANS; MALE; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 64649094164     PISSN: 15475271     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hrthm.2009.01.038     Document Type: Article

References (22)

1. Wilde A.A.M., Antzelevitch C., Borggrefe M., et al. Consensus report. Proposed diagnostic criteria for the Brugada syndrome. Eur Heart J 23 (2002) 1648-1654
2. Antzelevitch C., Brugada P., Borggrefe M., et al. Brugada syndrome. Report of the Second Consensus Conference. Circulation 111 (2005) 659-670
3. Yokokawa M., Noda T., and Okamura H. Comparison of long-term follow-up of electrocardiographic features in Brugada syndrome between the SCN5A-positive probands and the SCN5A-negative probands. Am J Cardiol 100 (2007) 649-655
4. Tan H.L., Bink-Boelkens M.T.E., Bezzina C.R., et al. A sodium-channel mutation causes isolated cardiac conduction disease. Nature 409 (2001) 1043-1046
5. Smits J.P.P., Eckardt L., Probst V., et al. Genotype-phenotype relationship in Brugada syndrome: electrocardiographic features differentiate SCN5A-related patients from non-SCN5A-related patients. J Am Coll Cardiol 40 (2002) 350-356
6. Junttila M.J., Brugada P., Hong K., et al. Differences in 12-lead electrocardiogram between symptomatic and asymptomatic Brugada syndrome patients. J Cardiovasc Electrophysiol 19 (2008) 380-383
7. Benito B., Brugada R., Brugada J., et al. Brugada syndrome. Prog Cardiovasc Dis 51 (2008) 1-22
8. Shimizu W., Matsuo K., Takagi M., et al. Body surface distribution and response to drugs of ST-segment elevation in Brugada syndrome: clinical implication of eighty-seven-lead body surface potential mapping and its application to twelve-lead electrocardiograms. J Cardiovasc Electrophysiol 11 (2000) 396-404
9. Sangwatanaroj S., Prechawat S., Sunsaneewitayakul B., et al. New electrocardiographic leads and the procainamide test for the detection of the Brugada sign in sudden unexplained death syndrome survivors and their relatives. Eur Heart J 22 (2001) 2290-2296
10. Teijeiro R., Garro H.A., Acunzo R.S., et al. Recording of high V1-V3 precordial leads may be essential to the diagnosis of Brugada syndrome during the ajmaline test. J Cardiovasc Pharmacol Ther 11 (2006) 153-155
11. Gasparini M., Priori S.G., Mantica M., et al. Flecainide test in Brugada syndrome: a reproducible but risky tool. Pacing Clin Electrophysiol 26 (2003) 338-341
12. Morita H., Morita T.S., Nagase S., et al. Ventricular arrhythmia induced by sodium channel blocker in patients with Brugada syndrome. J Am Coll Cardiol 42 (2003) 1624-1631
13. Chinushi M., Komura S., Izumi D., et al. incidence and initial characteristics of pilsicainide-induced ventricular arrhythmias in patients with Brugada syndrome. Pacing Clin Electrophysiol 30 (2007) 662-671
14. Rolf S., Bruns H.-J., Wichter T., et al. The ajmaline challenge in Brugada syndrome: diagnostic impact, safety, and recommended protocol. Eur Heart J 24 (2003) 1104-1112
15. Meregalli P.G., Ruijter J.M., Hofman N., et al. diagnostic value of flecainide testing in unmasking SCN5A-related Brugada syndrome. J Cardiovasc Electrophysiol 17 (2006) 857-864
16. Shimizu W., Antzelevitch C., Suyama K., et al. Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol 11 (2000) 1320-1329
17. Wilde A.A.M. Proarrhythmia related to sodium channel blockade: mechanisms, monitoring, prevention and management. Card Electrophysiol Rev 2 (1998) 136-141
18. Morganroth J., and Horowitz L.N. Flecainide: its proarrhythmic effect and expected changes on the surface electrocardiogram. Am J Cardiol 53 (1984) 89B-94B
19. Swerdlow C.D., Yu J.O., Jacobson E., et al. Safety and efficacy of intravenous quinidine. Am J Med 75 (1983) 36-42
20. Wolpert C., Echternach C., Veltmann C., et al. Intravenous drug challenge using flecainide and ajmaline in patients with Brugada syndrome. Heart Rhythm 2 (2005) 254-260
21. Brugada R., Brugada J., Antzelevitch C., et al. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation 101 (2000) 510-515
22. Hong K., Brugada J., Oliva A., et al. Value of electrocardiographic parameters and ajmaline test in the diagnosis of Brugada syndrome caused by SCN5A mutations. Circulation 110 (2004) 3023-3027